ArticleBJUI compass2022
Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results.
Article in BJUI compass, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Complication Profile and Safety Outcomes of Aquablation in the Management of BPH.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Complication rate across the minimally invasive surgical treatments (MISTs): where do we stand? A systematic review of the literature.Prostate cancer and prostatic diseases · 2025Pooled it
- Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review.Frontiers in endocrinology · 2023Pooled it
- The impact of prostate size on outcomes of aquablation: a prospective study.World journal of urology · 2026Article
- The future of robotic surgery in the age of artificial intelligence.Nature reviews. Urology · 2026Review
- Real-World outcomes of aquablation for benign prostatic hyperplasia: a comparative analysis of the international collaborative aquablation research urology society (ICARUS) database, WATER and WATER-II trials.World journal of urology · 2026Article
- P.I. nomogram: an exploratory imaging-derived model for predicting early urinary incontinence following ThuLEP.World journal of urology · 2026Article
- The 21st century marks a rise in TURP retreatment rates: an analysis of Veterans Health Administration data.World journal of urology · 2025Article
- A Narrative Review of Robotic Aquablation in Benign Prostatic Hyperplasia Care: Where We Are Now.Cureus · 2025Review
- Aquablation versus HoLEP in patients with benign prostatic hyperplasia: a comparative prospective non-randomized study.World journal of urology · 2024Article
- Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation.Prostate cancer and prostatic diseases · 2024Review
- The prostatic middle lobe: clinical significance, presentation and management.Nature reviews. Urology · 2023Review
- Treatment Algorithm for Management of Benign Prostatic Obstruction: An Overview of Current Techniques.Life (Basel, Switzerland) · 2023Review
- Outcomes of holmium laser enucleation of the prostate (HoLEP) for very large-sized benign prostatic hyperplasia (over 150 mL): open simple prostatectomy is dead.World journal of urology · 2023Article
- Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results.The Journal of urology · 2023Article
- CUA 2022 Annual Meeting Abstracts - Podium Session 1: BPH, GU Trauma and Reconstruction, Neurogenic Bladder, Urinary Incontinence and Voiding Dysfunction, Pediatrics Friday, June 24, 2022 • 13:30-14:30.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Adapting to the long pandemic.BJUI compass · 2022Article
- Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results.BJUI compass · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 15 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this study is to determine if Aquablation therapy can maintain its effectiveness in treating men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with large-volume (80-150 cc) prostates at 3 years. Subjects and Methods: One hundred one men with moderate-to-severe BPH symptoms and prostate volumes between 80 and 150 cc were enrolled in a prospective, nonrandomized, multicenter, international clinical trial in late 2017. Baseline, procedural, and follow-up parameters were recorded at baseline and scheduled postoperative visits. IPSS, Qmax, and treatment failure are reported at 3 years. Results: The mean prostate volume was 107 cc (range 80-150). Mean IPSS improved from 23.2 at baseline to 6.5 at 3 years (16.3-point improvement, Conclusions: Three-year follow-up demonstrates a sustained symptom reduction response along with low irreversible complications to Aquablation in men with LUTS due to BPH and prostates of 80-150 cc. Current treatment options available for men with prostates of this size have similar efficacy outcomes but are burdened with high rates of irreversible complications. There are now numerous clinical studies with Aquablation used in various prostates sizes, and it should be offered as an option to men with LUTS due to BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.